Carvykti is another CAR T-cell therapy used for treating relapsed or refractory multiple myeloma. Similar to Abecma, it involves modifying a patient's own T cells to target the B-cell maturation antigen (BCMA) on the surface of myeloma cells. The modified T cells are infused back into the patient to help the immune system recognize and destroy cancer cells.

Carvykti is used for patients who have undergone at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. Clinical trials have shown significant response rates in patients treated with Carvykti, offering a new hope for those who have not responded to previous treatments.